Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return

Bulletin Express

05/06

Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.

The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.

No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.

The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1165791757"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165791757\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165791757?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165791757","market":"hk","top_or_hot":-1,"title":"Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.</p>\n<p>The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.</p>\n<p>No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.</p>\n<p>The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-05-06 17:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.</p>\n<p>The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.</p>\n<p>No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.</p>\n<p>The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1165791757","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165791757","pubTimestamp":1778059409,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"Bio-heart确认2026年4月股本稳定及公众持股量充足月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.\nThe authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.\nNo shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.\nThe company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}